18 completed, 6 recruiting, 5 unknown, 4 not yet recruiting. 37 Phase 2, 8 Phase 3, 5 Phase 1.
Follow Glucocorticoids: new trials by email Literature Review of Glucocorticoids trials Research Report on Glucocorticoids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-10-30 | 2026-11-09 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Momelotinib, Glucocorticoids, Placebo - VEXAS Syndrome | Phase 2 / Phase 3 | Not yet recruiting | GlaxoSmithKline | 136 | 2026-08-05 | 2026-06-01 |
| Bosentan in the Treatment of Giant Cell Arteritis Bosentan, Glucocorticoids - Giant Cell Arteritis (GCA) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 40 | 2026-06-01 | 2026-05-06 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. CM313 (SC), Glucocorticoids - Pemphigus Disease, Pemphigus Vulgaris (PV) | Phase 1 / Phase 2 | Not yet recruiting | Chao Ji | 100 | 2025-10-01 | 2024-10-29 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| A Clinical Trial With KJ103 in Anti-GBM Disease KJ103 for Injection, Cyclophosphamide, Glucocorticoids - Anti-Glomerular Basement Membrane Disease | Phase 2 | Active not recruiting | Shanghai Bao Pharmaceuticals Co., Ltd. | 12 | 2024-10-21 | 2025-06-13 |
| Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Adalimumab, Prednisone - Inflammatory Arthritis, Immune-related Adverse Event | Phase 2 | Recruiting | Tom Appleton | 30 | 2024-04-15 | 2026-03-03 |
| Rescue of Nephrons With ALE.F02 (RENAL-F02) ALE.F02, Rituximab, GlucoCorticoid - Glomerulonephritis Rapidly Progressive | Phase 2 | Recruiting | Alentis Therapeutics AG | 80 | 2023-09-07 | 2026-08-14 |
| A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids - Neuromyelitis Optica Spectrum Disorders | Phase 2 | Recruiting | Guangzhou JOYO Pharma Co., Ltd | 35 | 2023-05-24 | 2024-11-20 |
| A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies Nipocalimab, Placebo, Glucocorticoids - Myositis | Phase 2 | Completed | Janssen Research & Development, LLC | 36 | 2022-07-05 | 2026-11-04 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 ABBV-154, Placebo, Glucocorticoid - Polymyalgia Rheumatica | Phase 2 | Terminated | AbbVie | 181 | 2021-09-09 | 2024-10-15 |
| MSC for Treatment of cGVHD After Allo-HSCT Mesenchymal stem cells, Glucocorticoids, cyclosporine - Chronic Graft-versus-host Disease | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 152 | 2021-01-10 | 2020-12-31 |
| Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants rilzabrutinib, Glucocorticoids - Immunoglobulin G4 Related Disease | Phase 2 | Completed | Principia Biopharma, a Sanofi Company | 27 | 2020-08-22 | 2025-10-14 |
| Twice Weekly Steroids and Exercise as Therapy for DMD Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Completed | University of Florida | 21 | 2020-07-30 | 2026-03-13 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Tocilizumab, Glucocorticoids - Giant Cell Arteritis | Phase 1 / Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 18 | 2018-12-01 | 2021-06-22 |
Showing 20 of 37. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Aspergillosis, Allergic Bronchopulmonary (4) · Giant Cell Arteritis (3) · Anemia (2) · Anemia, Aplastic (2) · Anemia, Hemolytic (2) · Arthritis (2) · Bone Marrow Failure Disorders (2) · Bronchiolitis Obliterans Syndrome (2) · Granulomatosis with Polyangiitis (2) · Hematologic Diseases (2) · Hemoglobinuria (2) · Hemoglobinuria, Paroxysmal (2) · Microscopic Polyangiitis (2) · Proteinuria (2)
Post Graduate Institute of Medical Education and Research, Chandigarh (4) · Insel Gruppe AG, University Hospital Bern (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Nanfang Hospital, Southern Medical University (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Alentis Therapeutics AG (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Chao Ji (1) · Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Cougar Biotechnology, Inc. (1) · First Affiliated Hospital of Zhejiang University (1)
China (12) · United States (8) · France (6) · United Kingdom (6) · Canada (5) · Germany (5) · Italy (5) · Spain (5) · Switzerland (5) · India (4) · Japan (4) · Czechia (3) · Denmark (2) · Hungary (2) · Netherlands (2)
Ritesh Agarwal, MD, DM (2) · Anja Pfaff, PhD (1) · Christian Larsen, MD (1) · Chunhua Zhao, MD,PHD (1) · Cougar Biotechnology, Inc. Clinical Trial (1) · Flavio Vincenti, MD (1) · He Huang, MD (1) · Jan Frystyk, Professor (1) · Juergen Braun, MD (1) · Kunshen Liu, MD (1) · Laimonas Griskevicius, MD (1)
PMID 21802835, PMID 26585431, PMID 26952547, PMID 28388956, PMID 28945869, PMID 29331473, PMID 29961816, PMID 30561849, PMID 31260678, PMID 31668569, PMID 31671877, PMID 33128347, PMID 34117737, PMID 37287970, PMID 38287611
2018 (1), 2023 (1), 2025 (1)